Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao ...

The tussle between IHH Healthcare Bhd, Asia’s biggest private healthcare provider, and Daiichi Sankyo Co Ltd, a ...

IHH's unit. The error also appeared in an earlier version of the story.)(Reuters) - IHH Healthcare said on Thursday its ...

Delhi: IHH Healthcare, a prominent global healthcare provider, has escalated its legal battle with Japan's Daiichi Sankyo, ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

IHH’s subsidiary Northern TK Venture (NTK) had filed a claim against Daiichi Sankyo saying the latter prevented NTK from ...

IHH Healthcare said on Thursday its unit has sought up to 109.3 billion rupees ($1.25 billion) in compensation from Japan's ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective ...

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

Northern TK Venture Pte Ltd, IHH Healthcare's Singaporean arm, has raised its claim against Daiichi Sankyo in Tokyo for ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...